HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fuster, J. L. Articles by Ortuño, F. J. Search for Related Content PubMed PubMed Citation Articles by Fuster, J. L. Articles by Ortuño, F. J.

Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia

^* Hospital Universitario Virgen de la Arrixaca, Murcia, Spain;
^° Clínica Solca, Guayaquil, Ecuador;
^# Hospital Morales Meseguer, Murcia, Spain

Correspondence: Jose Luis Fuster, Unidad de Oncohematología Pediátrica, Hospital Universitario Virgen de la Arrixaca, Ctra. Madrid-Cartagena s/n, El Palmar, 30120, Murcia, Spain. Phone: international +34.968369082/34.968369297. Fax: international +34.968369077. E-mail: josel.fuster{at}carm.es

The role of imatinib in childhood Philadelphia chromosome-positive (Ph⁺) acute lymphoblastic leukemia (ALL) has not been established. We treated four children with imatinib in combination with conventional chemotherapy (CT) before stem cell transplantation (SCT). Response evaluation consisted of fluorocytometric analysis of minimal residual disease (MRD) and standard qualitative RT-PCR follow-up.

Key words: Philadelphia chromosome, ALL, childhood, imatinib, chemotherapy.